Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mitsubishi Tanabe Pharma
Pharma
Astellas, Mitsubishi Tanabe, Leqembi—Fierce Pharma Asia
Astellas reprioritizes its investment focus. Bain buys Mitsubishi Tanabe for $3.3 billion. Eisai sees an upcoming Leqembi "expansion phase." And more.
Angus Liu
Feb 14, 2025 9:51am
Bain Capital lays out $3.3B to acquire Mitsubishi Tanabe Pharma
Feb 7, 2025 11:26am
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Jan 10, 2025 9:00am
Merck's GLP-1 play; Astellas' AAV deal—Fierce Pharma Asia
Dec 20, 2024 8:51am
Sanofi, GSK and China reimbursement updates—Fierce Pharma Asia
Dec 6, 2024 9:00am
FDA snubs AbbVie's blockbuster-to-be Parkinson's drug
Mar 22, 2023 11:50am
